Clinical trial
ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT…
NCT00346749 · GlaxoSmithKline, Industry · Terminated
Key facts
| NCT number | NCT00346749 |
|---|---|
| Title | ADVAIR DISKUS® (Fluticasone Propionate/Salmeterol) Inhaler Versus SEREVENT DISKUS® (Salmeterol) Inhlaer On Inflammatory Cells And Markers In Chronic Obstructive Pulmonary Disease. ADVAIR DISKUS® and SEREVENT DISKUS® Inhalers Are Trademarks of the GSK Group of Companies. |
| Official title | A Randomized, Double-Blind, Parallel-Group, 12-Week Study to Evaluate the Anti-Inflammatory Effect of Fluticasone Propionate/Salmeterol DISKUS 250/50mcg BID Compared With Salmeterol DISKUS 50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD) |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Terminated |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Pulmonary Disease, Chronic Obstructive |
| Intervention type | Drug |
| Interventions | Salmeterol, Fluticasone Propionate/Salmeterol Combination Product |
| Enrollment | 180 |
| Start date | Dec 1, 2006 |
| Primary completion | Jul 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Jun 30, 2006 |
| Last update posted | Oct 28, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: